Advertisement

Roche extends hostile $5.7 billion Illumina bid

Share this article

12:53 CEST+02:00

Swiss pharmaceutical giant Roche on Monday extended its hostile $5.7 billion bid for US gene mapper Illumina by four weeks.

"Roche announced today that it has extended its cash tender offer to acquire all outstanding shares of Illumina, Inc., at a price of $44.50 per share, to 6:00 p.m., New York City time, on April 20th, 2012," the Basel-based group said.

The group's previous offer ran until March 23rd, but it has so far only received shares worth about $6.4 million.

Roche claims that its offer is 64 percent higher than Illumina's closing price on December 21st, 2011 -- "the day before market rumours" of the bid sent the stock higher.

Story continues below…

But Illumina, a provider of integrated systems for DNA sequencing, had opposed the hostile bid, saying it "does not reflect Illumina's unique leadership position, business performance and future prospects."

Share this article

Advertisement

From our sponsors

How to get British healthcare no matter where you are

Navigating the health care system in another country can be tough, and even when it all works out, sometimes you just miss the comfort of the system back home. But there's a solution.

Advertisement
Advertisement
Advertisement

Popular articles

Advertisement
Advertisement